2-氯甲基-5-(4-氯苯)-1,3,4-氧代二唑 | 24068-15-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯甲基-5-(4-氯苯)-1,3,4-氧代二唑
• 中文别名: 2-氯甲基-5-(4-氯苯基)-1,3,4-氧二唑
• 英文名称: 2-(chloromethyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole
• 英文别名: 5-(4-chlorophenyl)-2-(chloromethyl)-1,3,4-oxadiazole
• CAS: 24068-15-3
• 化学式: C₉H₆Cl₂N₂O
• mdl: MFCD00714902
• 分子量: 229.065
• InChiKey: AJKIAERFLWQLAM-UHFFFAOYSA-N

物化性质

• 熔点：
  81-85 °C
• 密度：
  1.4813 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 储存条件：
  存放于阴凉干燥处

SDS

Name:	2-Chloromethyl-5-(4-Chlorophenyl)-1 2 4-Oxadiazole 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	24068-15-3

Section 1 - Chemical Product MSDS Name:2-Chloromethyl-5-(4-Chlorophenyl)-1 2 4-Oxadiazole 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
24068-15-3	2-Chloromethyl-5-(4-Chlorophenyl)-1,2,	98%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Avoid contact with skin and eyes. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 24068-15-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 81- 85 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H6Cl2N2O
Molecular Weight: 228.9608

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 24068-15-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Chloromethyl-5-(4-Chlorophenyl)-1,2,4-Oxadiazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 24068-15-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 24068-15-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 24068-15-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯甲基-5-(4-氯苯)-1,3,4-氧代二唑 在 硫脲 作用下， 以 四氢呋喃 为溶剂， 以78%的产率得到2-氯甲基-5-(4-氯苯基)-1,3,4-噻二唑
  参考文献：
  名称：

  2-（双（（（1,3,4-恶二唑基/ 1,3,4-噻二唑基）甲硫基）甲硫基）亚甲基）丙二腈的合成及生物活性

  摘要：

  研究了在不同当量乙醇钠存在下乙烯酮二硫醇盐的反应性。2-（双（（（5-芳基-1,3,4-恶二唑-2-基）甲硫基）亚甲基）丙二腈5和2-（双（（5-芳基-1,3,4-噻二唑-2-基通过丙二腈与二硫化碳和5-芳基-2-（氯甲基）-1,3,4-恶二唑3 / 5-芳基-2-（氯甲基）-1,3的反应制备）甲硫基）亚甲基）丙二腈6，4-噻二唑4。测定了先导化合物的初步抗微生物和抗氧化活性。

  DOI：

  10.1016/j.ejmech.2011.01.063
• 作为产物：
  描述：

  对氯苯甲酸甲酯 在 肼 、 三氯氧磷 作用下， 以 乙醇 、 1,2-二氯乙烷 为溶剂， 反应 15.0h， 生成 2-氯甲基-5-(4-氯苯)-1,3,4-氧代二唑
  参考文献：
  名称：

  发现新型 furo[2,3-d]pyrimidin-2-one-1,3,4-oxadiazole 杂化衍生物作为诱导细胞凋亡的双重抗病毒和抗癌剂

  摘要：

  通过环境友好的多步合成工具和一锅 Songoashira-杂环化方案首次使用纳米结构合成了一系列新的呋喃[2,3 - d ]嘧啶-1,3,4-恶二唑杂化衍生物焦磷酸钯（Na 2 PdP 2 O 7）作为非均相催化剂。化合物9a-c对野生和突变水痘带状疱疹病毒 (VZV) 毒株表现出广谱活性，具有低微摩尔 EC 50值。化合物9b对胸苷激酶缺陷型 VZV 菌株的效力比参考药物阿昔洛韦高出三倍。重要的是，导数9b在最大测试浓度 (CC 50  > 100 µM) 下没有细胞抑制作用，并且具有高达 7.8 的可接受的选择性指数值。此外，对所有合成的 1,3,4-恶二唑杂合体在四种人类癌细胞系中的细胞毒活性进行了评估：纤维肉瘤 (HT-1080)、乳腺癌 (MCF-7 和 MDA-MB-231) 和肺癌 (A549) ）。数据显示，化合物8f表现出中等的细胞毒性，IC 50值范围为 13.89 至

  DOI：

  10.1002/ardp.202100146

文献信息

• Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety
  作者：Fatma A.F. Ragab、Sahar M. Abou-Seri、Salah A. Abdel-Aziz、Abdallah M. Alfayomy、Mohamed Aboelmagd

  DOI：10.1016/j.ejmech.2017.06.026

  日期：2017.9

  A series of dihydropyrimidine (DHPM) derivatives bearing 1,3,4-oxadiazole moiety was designed and synthesized as monastrol analogues. The new compounds were screened for their cytotoxic activity toward 60 cancer cell lines according to NCI (USA) protocol. Seven compounds were further examined against the most sensitive cell lines, leukemia HL-60(TB) and MOLT-4. The most active compounds were 9m against

  设计并合成了一系列带有1,3,4-恶二唑部分的二氢嘧啶（DHPM）衍生物，作为monastrol类似物。根据NCI（USA）方案，筛选了这些新化合物对60种癌细胞系的细胞毒活性。进一步针对最敏感的细胞系白血病HL-60（TB）和MOLT-4检测了7种化合物。活性最高的化合物对HL-60（TB）的 抗性为9m（IC 50  = 56 nM），对MOLT-4的活性为9n（IC 50 = 80 nM），比蒙那那尔更强（分别为IC 50  = 147和215 nM）。9m处理的HL-60（TB）细胞和9n处理的MOLT-4细胞的细胞周期分析 如膜联蛋白V-FITC染色所显示的，显示出在G2 / M期的细胞周期停滞和促凋亡活性。
• Synthesis and Antimicrobial Evaluation of Aminoguanidine and 3-amino- 1,2,4-triazole Derivatives as Potential Antibacterial Agents
  作者：Tian-Yi Zhang、Chao Li、Ya-Ru Li、Xiao-Zhen Li、Liang-Peng Sun、Chang-Ji Zheng、Hu-Ri Piao

  DOI：10.2174/1570180813666160819151239

  日期：2016.10.31

  A series of aminoguanidine derivatives bearing a 1,3,4-oxadiazole or piperazine moiety has been synthesized and fully characterized together with a series of 3-amino-1,2,4-triazole derivatives, and the resulting compounds were evaluated for their anti-bacterial activity. Most of these compounds showed broad-spectrum antibacterial activities against both Gram-positive and Gram-negative bacteria with

  已合成了一系列带有1,3,4-恶二唑或哌嗪部分的氨基胍衍生物，并与一系列3-氨基-1,2,4-三唑衍生物一起进行了全面表征，并评估了所得化合物的抗-细菌活性。这些化合物大多数对革兰氏阳性和革兰氏阴性细菌均具有广谱抗菌活性，其最低抑菌浓度（MIC）和最低杀菌浓度（MBC）值在1–64μg/ mL范围内，包括耐多药临床分离株和真菌。值得注意的是，化合物19e和19f的抗甲氧西林金黄色葡萄球菌（3167和3506）和喹诺酮抗S的活性高于加替沙星和莫西沙星。金黄色葡萄球菌（3505和3519）的MIC和MBC值在1-2 µg / mL范围内。这两种化合物还显示出显着的抗真菌活性，对白色念珠菌7535的MIC值为1μg/ mL，相当于标准药物氟康唑的MIC值。因此，这些结果表明，不含哌嗪部分的氨基胍衍生物是开发新型抗菌剂的令人感兴趣的支架。
• Thiazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20020025976A1

  公开（公告）日：2002-02-28

  Diaminothiazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  二氨基噻唑化合物可调节和/或抑制特定蛋白激酶的活性。这些化合物及含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies
  作者：Abdallah M. Alfayomy、Salah A. Abdel-Aziz、Adel A. Marzouk、Montaser Sh. A. Shaykoon、Atsushi Narumi、Hiroyuki Konno、Sahar M. Abou-Seri、Fatma A.F. Ragab

  DOI：10.1016/j.bioorg.2020.104555

  日期：2021.3

  Two new series of 1,3,4-oxadiazole and coumarin derivatives based on pyrimidine-5-carbonitrile scaffold have been synthesized and evaluated for their COX-1/COX-2 inhibitory activity. Compounds 10c, 10e, 10h-j, 14e-f, 14i and 16 were found to be the most potent and selective inhibitors of COX-2 (IC50 0.041-0.081 μM, SI 139.74-321.95). Eight compounds were further investigated for their in vivo anti-inflammatory

  合成了两个新系列的基于 pyrimidine-5-carbonitrile 支架的 1,3,4-恶二唑和香豆素衍生物，并评估了它们的 COX-1/COX-2 抑制活性。发现化合物10c、10e、10h-j、14e-f、14i和16是最有效和选择性的 COX-2 抑制剂（IC 50 0.041-0.081 μM，SI 139.74-321.95）。进一步研究了八种化合物的体内抗炎活性。最活跃的衍生物10c , 10j和14e显示出优于参考药物塞来昔布的体内抗炎活性（水肿抑制百分比 39.3-48.3，1 小时；58.4-60.5，2 小时；70.8-83.2，3 小时；78.9-89.5，4 小时）（水肿抑制百分比 38.0） ，1 小时；48.8、2 小时；58.4、3 小时；65.4、4 小时）。还测试了这些衍生物的致溃疡倾向，化合物10j与塞来昔布相比表现出更好的安全性，而10c和14e表现出轻度损伤。COX-2
• Design, synthesis and biological evaluation of 2-(phenoxymethyl)-5-phenyl-1,3,4-oxadiazole derivatives as anti-breast cancer agents
  作者：K. Lakshmithendral、K. Saravanan、R. Elancheran、K. Archana、N. Manikandan、H.A. Arjun、M. Ramanathan、N.K. Lokanath、S. Kabilan

  DOI：10.1016/j.ejmech.2019.02.033

  日期：2019.4

  molecular docking approach revealed the findings of 2-(phenoxymethyl) -5-phenyl-1,3,4-oxadiazole derivatives. The compounds (7a-o) were synthesized and characterized well by using conventional methods. The compounds, 7b and 7m were reconfirmed through single crystal XRD analysis. The synthesized compounds (7a-o) were evaluated their antiproliferative activities against MCF-7 and MDA-MB-453. Furthermore

  基于结构的分子对接方法揭示了2-（苯氧基甲基）-5-苯基-1,3,4-恶二唑衍生物的发现。通过使用常规方法合成并很好地表征了化合物（7a-o）。通过单晶XRD分析确认化合物7b和7m。评价了合成的化合物（7a-o）对MCF-7和MDA-MB-453的抗增殖活性。此外，对测试化合物预测了Lipinski的5法则和药代动力学特性。这些结果表明，化合物7b和7d显示出更强的细胞毒性，而7d表现出剂量依赖性活性和降低的细胞活力。此外，通过形态变化和蛋白质印迹分析观察到了诱导的细胞凋亡的作用机理。这些发现可能为进一步发展提供线索。